Exploring YAP1-related TIME in SCLC: implications for survival and treatment response to immuno-chemotherapy

Abstract

Aim: Small-cell lung cancer (SCLC) is usually diagnosed as an advanced stage with a poor outcome. SCLC has limited response to immunotherapy due to the absence or lack of immune cell infiltration, so studying its tumor immune microenvironment (TIME) is essential.

Methods: The study involved patients with extensive-stage small-cell lung cancer (ES-SCLC) diagnosed at the Guangdong Lung Cancer Institute between January 2018 and April 2022 who had received the atezolizumab/carboplatin/etoposide (ECT) treatment. We used multi-immunohistochemistry (mIHC) to assess the prognostic value of YAP1 and TIME in SCLC, with results confirmed using public data.

Results: 15 patients with sufficient baseline biopsy samples were included in this study. The total population of YAP1-positive cells is inversely related to progression-free survival (PFS) and shows a potential negative correlation with overall survival (OS). CD56-positive cells are the primary components of TIME in SCLC tumor parenchyma and stroma. The total population and cell density of YAP1-positive cells are significantly positively correlated with CD4-positive cells. Furthermore, in the tumor parenchyma, both the proportion and the cell density of YAP1-positive cells are positively correlated with that of FOXP3-positive cells. The total population of CD56-positive cells showed a negative correlation trend with YAP1-positive cells but without significant difference.

Conclusion: YAP1 has shown prognostic value in SCLC patients receiving ECT regimen treatment. The high expression level of YAP1 seems related to the inhibitory TIME. However, some prospective studies with larger populations are warranted.

Keywords

Small-cell lung cancer / YAP1 / immunotherapy / tumor immune microenvironment / CD4 T cell

References

[1] Leiter A,Wisnivesky JP.The global burden of lung cancer: current status and future trends.Nat Rev Clin Oncol2023;20:624-39

[2] Planchard D, Jänne PA, Cheng Y, et al; FLAURA2 Investigators. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389:1935-48.

[3] Mok T,Park K.Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722.J Clin Oncol2024;42:1252-64 PMCID:PMC11095864

[4] Rudin CM,Faivre-Finn C.Small-cell lung cancer.Nat Rev Dis Primers2021;7:3 PMCID:PMC8177722

[5] Wang S,Sun T.Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages.Sci Rep2017;7:1339 PMCID:PMC5431017

[6] Ganti AKP,Bassetti M.Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw2021;19:1441-64 PMCID:PMC10203822

[7] National Comprehensive Cancer Network. Small cell lung cancer (Version 2.2024). https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462. (accessed 2025-02-12)

[8] Horn L, Mansfield AS, Szczęsna A, et al; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-9.

[9] European Medicines Agency. Tecentriq: European public assessment report (EPAR). https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq. (accessed 2025-02-12)

[10] Elia I.Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism.Nat Metab2021;3:21-32 PMCID:PMC8097259

[11] Banerjee A,Kanna NRR.Role of tumor specific niche in colon cancer progression and emerging therapies by targeting tumor microenvironment.Adv Exp Med Biol2021;1341:177-92

[12] Roller A,Schwalie PC.Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials.J Immunother Cancer2024;12:e008185 PMCID:PMC11043740

[13] Tang H,Ge H.Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.Int Immunopharmacol2024;133:112053

[14] Guo Y,Hu P.Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy.Nat Commun2023;14:7306 PMCID:PMC10640620

[15] Enfield KSS, Colliver E, Lee C, et al; TRACERx consortium. Spatial architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer. Cancer Discov. 2024;14:1018-47. PMCID:PMC7614605

[16] Cao J.Identification of immune infiltration and prognostic biomarkers in small cell lung cancer based on bioinformatic methods from 3 studies.Comb Chem High Throughput Screen2023;26:507-16

[17] Chan JM,Gao VR.Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer.Cancer Cell2021;39:1479-96.e18 PMCID:PMC8628860

[18] Spigel DR.Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.J Thorac Oncol2013;8:587-98

[19] Remon J,Besse B.Small cell lung cancer: a slightly less orphan disease after immunotherapy.Ann Oncol2021;32:698-709

[20] Tian Y,Han A,Yu J.Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.J Hematol Oncol2019;12:67 PMCID:PMC6599302

[21] Huang J,Barrera J,Pan D.The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP.Cell2005;122:421-34

[22] Vigneswaran K,Oh SY.YAP/TAZ transcriptional coactivators create therapeutic vulnerability to verteporfin in EGFR-mutant glioblastoma.Clin Cancer Res2021;27:1553-69 PMCID:PMC8440125

[23] Szulzewsky F,Vasioukhin V.YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance.Dev Biol2021;475:205-21 PMCID:PMC8107117

[24] Rudin CM,Byers LA.Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.Nat Rev Cancer2019;19:289-97 PMCID:PMC6538259

[25] Keogh A,Radonic T.Emerging biomarkers and the changing landscape of small cell lung cancer.Cancers2022;14:3772 PMCID:PMC9367597

[26] Chen YQ,Kong LC.The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients.Cancer Treat Res Commun2023;35:100684

[27] Carter BW,Truong MT.Small cell lung carcinoma: staging, imaging, and treatment considerations.Radiographics2014;34:1707-21

[28] Feng SH.The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations.Diagn Interv Radiol2019;25:270-9 PMCID:PMC6622436

[29] Schwartz LH,Litière S.RECIST 1.1 - Standardisation and disease-specific adaptations: perspectives from the RECIST Working Group.Eur J Cancer2016;62:138-45 PMCID:PMC5737786

[30] George J,Jang SJ.Comprehensive genomic profiles of small cell lung cancer.Nature2015;524:47-53 PMCID:PMC4861069

[31] Jeschke J,Desmedt C.DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.J Clin Invest2017;127:3090-102 PMCID:PMC5531413

[32] Xiao Y, Ma D, Zhao S, et al; AME Breast Cancer Collaborative Group. Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer. Clin Cancer Res. 2019;25:5002-14.

[33] Liu SV,Mansfield AS.Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133).J Clin Oncol2021;39:619-30 PMCID:PMC8078320

[34] Nishio M,Atagi S.Subgroup analysis of Japanese patients in a phase III study of atezolizumab in extensive-stage small-cell lung cancer (IMpower133).Clin Lung Cancer2019;20:469-76.e1

[35] Elegbede AA,Fung AS.A real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with extensive-stage SCLC in Canada.JTO Clin Res Rep2021;2:100249 PMCID:PMC8628038

[36] Lee S,Ahn BC.Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience.Cancer Immunol Immunother2022;71:1093-101 PMCID:PMC10991652

[37] Yang Y,Liu X.Comprehensive analysis of gene regulation network and immune signatures of prognostic biomarker YAP1 in pancreatic cancer.J Cancer2020;11:6960-9 PMCID:PMC7592007

[38] Zhou Q,Andersson R.YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling.J Transl Med2020;18:77 PMCID:PMC7017485

[39] Lee KW,Kim SB.Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients.Clin Cancer Res2015;21:357-64 PMCID:PMC4513664

[40] Wu Y,Xu P.The prognostic value of YAP1 on clinical outcomes in human cancers.Aging2019;11:8681-700 PMCID:PMC6814621

[41] Chen P,Wang H.YAP1 expression is associated with survival and immunosuppression in small cell lung cancer.Cell Death Dis2023;14:636 PMCID:PMC10522695

[42] Baine MK,Lai WV.SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization.J Thorac Oncol2020;15:1823-35 PMCID:PMC8362797

[43] Megyesfalvi Z,Lantos A.Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.J Pathol2022;257:674-86 PMCID:PMC9541929

[44] Freeman AJ,Ramsbottom KM.Natural killer cells suppress T cell-associated tumor immune evasion.Cell Rep2019;28:2784-94.e5

[45] Dhatchinamoorthy K,Rock KL.Cancer immune evasion through loss of MHC class I antigen presentation.Front Immunol2021;12:636568 PMCID:PMC7986854

[46] Bouzidi L,Charfi S.Prognostic value of natural killer cells besides tumor-infiltrating lymphocytes in breast cancer tissues.Clin Breast Cancer2021;21:e738-47

[47] Bisheshar SK,Devriese LA.The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.Oncoimmunology2020;9:1747345 PMCID:PMC7185215

[48] Villegas FR,Villarrubia VG.Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer.Lung Cancer2002;35:23-8

[49] Pockley AG,Multhoff G.NK cell-based therapeutics for lung cancer.Expert Opin Biol Ther2020;20:23-33

[50] Owonikoko TK,Chen Z.YAP1 expression in SCLC defines a distinct subtype with T-cell-inflamed phenotype.J Thorac Oncol2021;16:464-76 PMCID:PMC7920957

[51] Oh DY.Cytotoxic CD4⁺ T cells in cancer: expanding the immune effector toolbox.Immunity2021;54:2701-11 PMCID:PMC8809482

[52] Speiser DE,Schaeuble K.CD4⁺ T cells in cancer.Nat Cancer2023;4:317-29

[53] Wang W,McLaren F.Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate.Int J Cancer2012;131:E928-37

[54] Oliveira G,Cieri N.Landscape of helper and regulatory antitumour CD4⁺ T cells in melanoma.Nature2022;605:532-8 PMCID:PMC9815755

[55] Jiang Y,Cheng Q.Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy.Int Immunopharmacol2024;141:112901

[56] Qu S,Thomas A.Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.J Thorac Oncol2022;17:141-53 PMCID:PMC8692365